AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Delta-Fly Pharma, Inc. Initiated Phase 3 Clinical Study of DFP-10917 and Phase 1 Clinical Study of DFP-14927

November 26, 2019

TOKUSHIMA, Japan--(BUSINESS WIRE)--Nov 26, 2019--

Delta-Fly Pharma, Inc. (TOKYO: 4598) announces that patients have registered for clinical studies in the USA on anti-cancer drug candidates DFP-10917 and DFP-14927.

DFP-10917 is an anti-cancer agent in development for the treatment of patients with Refractory/Relapsed Acute Myelogenous Leukemia. A Phase 3 clinical study at MD Anderson Cancer Center in Texas, USA and other sites in the USA is underway.
Two patients at UT Southwestern Medical Center in Texas and Banner MD Anderson Cancer Center in Arizona registered for this study in November 2019.

In addition, a Phase 1 clinical study of DFP-14927, the polymeric delivery of DFP-10917 in patients with advanced solid tumors has been initiated at MD Anderson Cancer Center.
Two patients registered for this study in October of this year and treatment is ongoing.

Company’s profile

Company name

   

Delta-Fly Pharma, Inc. [TOKYO:4598]

Capital

   

2849 million Japanese Yen

Name and Title of Representative

   

Kiyoshi Eshima, PhD, President

Date of Incorporation

   

December 6, 2010

Description of Business

   

Research and development, manufacturing and marketing of pharmaceuticals

Head Office

   

37-5, Nishikino, Miyajima, Kawauchi-cho, Tokushima 771-0116, Japan

Branch Office

   

Tokyo, Beijing, Vancouver

 

View source version on businesswire.com:https://www.businesswire.com/news/home/20191126005329/en/

CONTACT: Delta-Fly Pharma, Inc.

Inquiries: Yasuo Matsueda 

TEL: +81-(0)3-6231-1278

ymatsueda1206@delta-flypharma.co.jp

https://www.delta-flypharma.co.jp/

KEYWORD: NORTH AMERICA UNITED STATES ASIA PACIFIC EUROPE JAPAN TEXAS ARIZONA

INDUSTRY KEYWORD: ONCOLOGY HEALTH CLINICAL TRIALS RESEARCH PHARMACEUTICAL SCIENCE

SOURCE: Delta-Fly Pharma, Inc.

Copyright Business Wire 2019.

PUB: 11/26/2019 04:13 AM/DISC: 11/26/2019 04:13 AM

http://www.businesswire.com/news/home/20191126005329/en